17,261 trials
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 — 41.5; 46.8; 43.4 percentage of participants — p=0.422
Multiple Myeloma
Primary: The Maximum Tolerated Dose of Bortezomib (MTD) — 1.6 mg/m2 of bortezomib
Prostate Adenocarcinoma · Stage IIB Prostate Cancer AJCC v8 · Stage IIC Prostate Cancer AJCC v8
Primary: The Number of Participants With Rate of Pathologic Stage =< pT2N0 at Prostatectomy — 13; 12 Participants
Plaque Psoriasis
Primary: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6 — 28.0; 22.8; 8.3 percentage of participants…
Breast Cancer · Cancer
Primary: The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase — 0; 2; 0 Participants
Spinal Cord Injuries
Primary: 10 Meter Walk Time — -5.0; -4.9; -4.6; -5.5 Seconds
Neurofibromatosis 1 · Cutaneous Neurofibroma
Primary: Phospho-erk (p-ERK) Levels of Target cNF Tumors in NFX-179 Gel Group and Vehicle Gel Group After 28 Days of Once-daily (QD) Application — 0.3054; 0.2734; 0.2267; 0.1627…
Sickle Cell Disease
Primary: 25 (OH)D in Nmol/L Between Baseline and 6 Months — 55.2; 50.4 nmol/L — p=0.0507
Polycystic Kidney, Autosomal Dominant
Primary: Change in the Gastrointestinal Symptoms Rating Scale (GSRS) to 24 Months — -0.04; -0.11 score on a scale — p=0.50
Non-obstructive Hypertrophic Cardiomyopathy
Primary: Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) — 88.9; 90.5; 68.4 percentage of participants
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Number of Participants Experiencing Adverse Events (AEs) — 248; 25; 31 Participants
Pain · Postoperative Pain · Pain, Acute
Primary: Overall Summed Pain Intensity Difference (SPID) — 109.5; 111.8; 108.8; 108.6 score on a scale * hours — p=0.003
Alpha 1-Antitrypsin Deficiency
Primary: Treatment-emergent Adverse Events Related to ADVM-043 — 0; 1; 2 Participants
Opioid Dependence · Opioid Withdrawal · Sleep Disturbance
Primary: Abuse Liability as Assessed by Visual Analogue Scale — 23.9; 20.9; 22.8 score on a scale*days — p=.950
Leukemia · Myelodysplastic Syndrome · Lymphoma
Primary: Percent of Engrafted Participants With Successful Neutrophil Recovery — 96 % w/incidence of neutrophil recovery